99 related articles for article (PubMed ID: 9458302)
1. Effects on host of modified PVP therapy combined with biological response modifiers in lung cancer.
Katoh R; Takenoshita S; Shimizu Y; Tanaka S; Yajima Y; Nagamachi Y
Oncol Rep; 1998; 5(1):103-7. PubMed ID: 9458302
[TBL] [Abstract][Full Text] [Related]
2. Changes in serum soluble IL-2 receptors (sIL-2R) and immunosuppressive acidic protein (IAP) associated with chemotherapy for lung cancer.
Katoh R; Takenoshita S; Shimizu Y; Tanaka S; Yajima Y; Nagamachi Y
Anticancer Res; 1997; 17(5B):3787-92. PubMed ID: 9427781
[TBL] [Abstract][Full Text] [Related]
3. Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatment.
Fokkema E; De Vries EG; Groen HJ; Meijer C; Timens W
Virchows Arch; 2003 Apr; 442(4):349-55. PubMed ID: 12715170
[TBL] [Abstract][Full Text] [Related]
4. A retrospective analysis of patients receiving surgery after chemotherapy for small cell lung cancer.
Yamada K; Saijo N; Kojima A; Ohe Y; Tamura T; Sasaki Y; Eguchi K; Shinkai T; Goya T; Kondou H
Jpn J Clin Oncol; 1991 Feb; 21(1):39-45. PubMed ID: 1648633
[TBL] [Abstract][Full Text] [Related]
5. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
6. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.
Viviani S; Camerini E; Bonfante V; Santoro A; Balzarotti M; Fornier M; Devizzi L; Verderio P; Valagussa P; Bonadonna G
Br J Cancer; 1998 Mar; 77(6):992-7. PubMed ID: 9528846
[TBL] [Abstract][Full Text] [Related]
7. [Small-cell lung cancer diagnostic and therapeutic recommendations of Polish Lung Cancer Group].
Krzakowski M; Orłowski T; Roszkowski K; Reinfuss M; Olszewski W; Ramlau R; Kowalski D; Konopa K; Jassem J; Jankowska R; Kozielski J; Wojtukiewicz M; Drosik K; Koralewski P;
Pneumonol Alergol Pol; 2007; 75(1):88-94. PubMed ID: 17541917
[TBL] [Abstract][Full Text] [Related]
8. Impact of splenectomy and immunochemotherapy on survival following gastrectomy for carcinoma: covariate interaction with immunosuppressive acidic protein, a serum marker for the host immune system. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Saji S; Sakamoto J; Teramukai S; Kunieda K; Sugiyama Y; Ohashi Y; Nakazato H
Surg Today; 1999; 29(6):504-10. PubMed ID: 10385364
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713.
Edelman MJ; Chansky K; Gaspar LE; Leigh B; Weiss GR; Taylor SA; Crowley J; Livingston R; Gandara DR
J Clin Oncol; 2004 Jan; 22(1):127-32. PubMed ID: 14701775
[TBL] [Abstract][Full Text] [Related]
10. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
[TBL] [Abstract][Full Text] [Related]
11. Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer.
Viviani S; Salvini PM; Bidoli P; Camerini E; Spinazzé S; Arienti F; Rivoltini L; Motta V
Int J Biol Markers; 1993; 8(1):21-4. PubMed ID: 8388428
[TBL] [Abstract][Full Text] [Related]
12. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.
Bonner JA; Sloan JA; Rowland KM; Klee GG; Kugler JW; Mailliard JA; Wiesenfeld M; Krook JE; Maksymiuk AW; Shaw EG; Marks RS; Perez EA
Clin Cancer Res; 2000 Feb; 6(2):597-601. PubMed ID: 10690544
[TBL] [Abstract][Full Text] [Related]
13. High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer.
Bessho A; Ueoka H; Kiura K; Tabata M; Sunami K; Katayama Y; Yamane H; Hiraki A; Harada M
Anticancer Res; 1999; 19(1B):693-8. PubMed ID: 10216478
[TBL] [Abstract][Full Text] [Related]
14. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
[TBL] [Abstract][Full Text] [Related]
15. [VP-16 and VM-26 plus platinum drugs combined with radiotherapy in the treatment of small cell lung cancer].
Zeng P; Yin L; Luo B; Liu Z; Jin X
Hunan Yi Ke Da Xue Xue Bao; 1998; 23(6):587-9. PubMed ID: 10806778
[TBL] [Abstract][Full Text] [Related]
16. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U
Lung Cancer; 2006 Jul; 53(1):67-75. PubMed ID: 16713013
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
[TBL] [Abstract][Full Text] [Related]
18. Alternating chemotherapy and thoracic radiotherapy with concurrent cisplatin-etoposide for limited-stage small-cell carcinoma of the lung.
Murray N; Shah A; Brown E; Kostashuk E; Laukkanen E; Goldie J; Band P; Van den Hoek J; Murphy K; Sparling T
Semin Oncol; 1986 Sep; 13(3 Suppl 3):24-30. PubMed ID: 3020695
[TBL] [Abstract][Full Text] [Related]
19. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
Ardizzoni A; Fusco V; Pennucci C; Baldini E; Orsatti M; Vitale V; Bonavia M; Baracco F; Mereu C; Rosso R
Anticancer Res; 1991; 11(2):681-4. PubMed ID: 1648333
[TBL] [Abstract][Full Text] [Related]
20. Double-cycle, high-dose ifosfamide, carboplatin, and etoposide followed by peripheral blood stem-cell transplantation for small cell lung cancer.
Iwasaki Y; Nagata K; Nakanishi M; Natuhara A; Kubota Y; Ueda M; Arimoto T; Hara H
Chest; 2005 Oct; 128(4):2268-73. PubMed ID: 16236883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]